top of page

Search Results

453 items found for "Dr. Nicola Smith"

  • Coffee Break with pastries announcement of the aGEM award | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem

    Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Coffee Break with pastries announcement of the aGEM award Complimentary < Previous Session Next Session >

  • Mexico City Nocturnal Tour, Food and drinks | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem

    Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Mexico City Nocturnal Tour, Food and drinks Coming Soon < Previous Session Next Session >

  • Biased agonism at the GLP-1 receptor: from structure to animal models of disease

    Sexton is also a co-founder of Septerna Inc. " Patrick Sexton on the web CCeMMP Monash University Dr.

  • Session IX / Technology capsule: Light on aGPCR signaling and function | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem

    Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session IX / Technology capsule: Light on aGPCR signaling and function NovoiSMART - A new platform for GPCR antibody drug discovery Abstract Developing monoclonal antibody drugs against GPCRs and other multi-pass transmembrane targets, such as ion channels, remains a significant challenge. Novoprotein developed a NovoiSMART technology, utilizing mRNA-based immunization, which can overcome these obstacles by producing high-quality antibodies that more accurately mimic natural protein structures. This approach contrasts with other antigen forms like peptides or DNA, which face limitations in structural integrity and immunogenicity. mRNA technology, demonstrated in the success of COVID-19 vaccines, is emerging as a promising method for antibody discovery. Several case studies of GPCR and other multi-pass transmembrane targets are presented, including GPRC5D, Claudin 6 and Napi2b. These studies show that mRNA immunization yields higher antibody titers and greater epitope diversity compared to other methods. These examples underscore the potential of NovoiSMART technology in developing highly specific antibodies for complex targets, with implications for overcoming challenges like drug resistance and tumor escape. About Gavin Zhang Gavin is a currently a director of business and operations at Novoprotein Scientific. His research experience includes phylogenetics and cancer epigenetics. Gavin Zhang on the web LinkedIn < Previous Session Next Session >

  • Atypical Structure and Function of Typical Chemokine Receptors

    The Ramsey Lab Amy Ramsey on the web University of Toronto Pubmed Google Scholar LinkedIn Twitter Dr.

bottom of page